TCL1
TCL1 is a selective non-covalent inhibitor targeting the Pru domain of the Rpn-13 subunit in the 19S regulatory particle (19S RP) of the proteasome with an IC50 value of approximately 26 μM. TCL1 interferes with the recognition and transport of ubiquitinated proteins by Rpn-13, inhibits the degradation of proteins by the proteasome, and thus affects the balance of intracellular protein metabolism. TCL1 is promising for research of hematological malignancies.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- CAS 番号: 875165-39-2
- 分子式: C19H14BrClN4O2S
- 分子量:477.76
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
生物活性
化学情報
-
CAS 番号 875165-39-2
-
分子量 477.76
-
分子式 C19H14BrClN4O2S
-
SMILES
O=C(CC1SC2=NN=C(CC3=CC=C(C=C3)Br)N2N=C1C4=CC=C(Cl)C=C4)O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
純度とドキュメンテーション
参考文献
[1]. Loy CA, et al. ByeTAC: Bypassing E-Ligase-Targeting Chimeras for Direct Proteasome Degradation. J Med Chem. 2025 May 8;68(9):9694-9705. [Content Brief]
[2]. Winton VJ, et al. Deleterious Consequences of UDP-Galactopyranose Mutase Inhibition for Nematodes. ACS Chem Biol. 2017 Sep 15;12(9):2354-2361. [Content Brief]
[3]. Loy CA, et al. Discovery of a non-covalent ligand for Rpn-13, a therapeutic target for hematological cancers. Bioorg Med Chem Lett. 2023 Oct 15;95:129485. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)